United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,676,831.88. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

James Edgemond also recently made the following trade(s):

• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.

United Therapeutics Trading Down 1.0%

Shares of NASDAQ UTHR traded down $5.75 during midday trading on Friday, hitting $556.34. The company’s stock had a trading volume of 645,038 shares, compared to its average volume of 481,449. The business’s 50 day moving average is $565.98 and its two-hundred day moving average is $515.55. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market cap of $23.62 billion, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the company posted $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Bull Harbor Capital LLC bought a new position in United Therapeutics in the first quarter worth approximately $494,000. Strategic Investment Advisors MI grew its stake in United Therapeutics by 20.5% in the first quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock worth $5,782,000 after purchasing an additional 1,662 shares in the last quarter. Talon Private Wealth LLC bought a new position in United Therapeutics in the first quarter worth approximately $3,038,000. Finally, Royal Bank of Canada grew its stake in United Therapeutics by 3.3% in the first quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock worth $35,075,000 after purchasing an additional 1,864 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.